Highlights Incyte Corporation

Equities

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 14/03/2026 am IST			5-day change	1st Jan Change
92.54 ^USD	+0.55%		-3.54%	-6.31%

11/03	Incyte Corporation Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 08:30 AM
10/03	Incyte Corporation Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 09:20 AM

Highlights

07/03	Incyte Corporation Receives Complete Response Letter From FDA For Zynyz Supplemental Biologics License Application	CI
07/03	Incyte announces the European Commission approval of Zynyz® (retifanlimab) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC)	RE
07/03	Incyte Announces European Commission Approval of Zynyz (Retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal	CI
28/02	Sector Update: Health Care Stocks Advance Late Afternoon	MT
27/02	Eli Lilly and Company's Olumiant Recommends by CHMP for Approval of Expanded Use in the European Union for Adolescents with Severe Alopecia Areata	CI
27/02	Eli Lilly, Incyte Say They Get EMA Panel's Positive Opinion for Olumiant to Treat Severe Alopecia Areata	MT
18/02	United Medical Ltda Announces Regulatory Submission of NIKTIMVO in Brazil	CI
14/02	Incyte's weak Opzelura 2026 revenue forecast heightens Jakafi patent concerns (Feb 10)	RE
10/02	Incyte Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
10/02	Incyte Q4 Adjusted Earnings, Revenue Rise; Shares Down Pre-Bell	MT
10/02	Incyte Corporation Provides Earnings Guidance for the Fiscal Year 2026	CI
10/02	Earnings Flash (INCY) Incyte Corporation Reports Q4 Revenue $1.51B, vs. FactSet Est of $1.35B	MT
10/02	Earnings Flash (INCY) Incyte Corporation Posts Q4 Adjusted EPS $1.80 per Share, vs. FactSet Est of $2.44	MT
06/02	Diary - U.S. earnings week ahead	RE
03/02	Prelude Therapeutics Incorporated Receives FDA Clearance of Investigational New Drug Application for PRT12396	CI
30/01	Incyte Announces Positive CHMP Opinion for Zynyz®? (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal	CI
05/01	Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi/Minjuvi) as First-Line Treatment for Diffuse Large B-Cell Lymphoma	CI
05/01	Incyte announces positive topline results from study of tafasitamab	RE
22/12	Incyte Says Its Cancer Drug Has Received Approval in Japan for Follicular Lymphoma	MT
18/12	Incyte announces European Commission approval of Minjuvi (tafasitamab)	RE
17/12	Incyte Announces European Commission Approval of Minjuvi (Tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma	CI
17/12	Incyte Says European Commission Approves Minjuvi Combination Therapy for Follicular Lymphoma	MT
08/12	Incyte Says Rare Blood Cancer Therapy Receives FDA Breakthrough Designation	MT
07/12	Incyte Announces New Positive Data for INCA033989, Its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented At ASH 2025	CI
07/12	Incyte's First-In-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA	CI